/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. TBPN
  2. $2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng
$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng

TBPN · Mar 27, 2026

TBPN covers a $2B pharma deal, Anthropic's Mythos model, OpenAI's ad success, and defense tech. Plus, AI Director Billy Boman shares insights.

Normal Computing Targets Probabilistic AI With New Noisy Chip Architectures

Instead of competing on speed and energy alone, Normal Computing is designing ASICs that introduce noise as a third optimization vector. These chips are ideal for probabilistic workloads like diffusion models, which are inherently noisy and approximate, mapping the software's physics to the hardware's.

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng thumbnail

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng

TBPN·8 hours ago

The Best AI Tools Enable Previously Impossible Tasks, Not Just Time Savings

According to Moda's founder, the most impactful AI tools are not those that merely accelerate existing workflows. Instead, they are the ones that empower users to achieve outcomes that were previously beyond their skill set, truly unlocking new creative capabilities for non-experts.

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng thumbnail

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng

TBPN·8 hours ago

The Core Military AI Challenge Is Balancing Performance, Assurance, and Development Speed

Shield AI identifies the key problem in defense tech as simultaneously achieving high performance, ensuring high levels of safety and assurance, and maintaining rapid development cycles. Historically, systems had to trade these off, but modern defense requires solving for all three concurrently.

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng thumbnail

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng

TBPN·8 hours ago

Following Serial Acquirer CEOs Like Xcelergy's Is A Viable Biotech Investment Strategy

Xcelergy's CEO, Todd Zevodnik, sold the company for $2B in under a year, his third unicorn exit. This demonstrates that tracking and investing in companies led by operators with a proven playbook for rapid, high-value acquisitions can be a highly effective investment thesis.

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng thumbnail

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng

TBPN·8 hours ago

AI Ad Director Argues to Reinvest Budgets into Imagination, Not Cost-Cutting

Top AI creators advise against using AI simply to reduce ad budgets. The real competitive advantage lies in reallocating savings to produce more ambitious concepts that were previously impossible, thereby out-innovating competitors who are merely focused on efficiency gains.

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng thumbnail

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng

TBPN·8 hours ago

AI's Real Value in Pharma Is Accelerating Tedious FDA Paperwork, Not Just Drug Discovery

Pharmaceutical giants are adopting AI not for moonshot "cure cancer" prompts, but to streamline critical, error-prone processes like compiling 10,000-page FDA documents. This mundane application prevents costly delays and accelerates time-to-market for multi-billion dollar drugs.

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng thumbnail

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng

TBPN·8 hours ago

Even Top AI Labs Like Anthropic Face GPU Constraints, Vindicating Massive Capital Investments

Anthropic is throttling user access during peak hours due to GPU shortages. This confirms that the AI industry remains severely compute-constrained and validates the multi-billion dollar infrastructure investments by giants like OpenAI and Meta, which once seemed excessive.

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng thumbnail

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng

TBPN·8 hours ago

Top AI Creative Talent Comes from Diverse Fields like Anthropology, Not Just Film School

The new wave of leading AI directors and creators often have non-traditional backgrounds, such as fashion design or anthropology. This is because the crucial skills have shifted from technical software mastery to taste, art direction, and the ability to articulate a vision in natural language.

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng thumbnail

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng

TBPN·8 hours ago

OpenAI's Ad Platform Offers Early Adopters an "Alpha" Before Large Companies Optimize It

New ad platforms present a window of opportunity for nimble advertisers to achieve outsized results. Before large corporations move in and marketing becomes hyper-optimized, early adopters who can quickly master the new system can capture significant, cost-effective reach and engagement.

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng thumbnail

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng

TBPN·8 hours ago

Professional AI Creators Demand Better Human-Focused Interfaces, Not Just Better Models

An AI director's top request for AI labs is not more powerful models but more intuitive, human-centric user interfaces. The industry needs to move beyond simple text prompts and SaaSy dashboards to tools that offer artists fine-grained creative control and a more natural workflow.

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng thumbnail

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng

TBPN·8 hours ago

Shield AI Uses Physics-Based Simulation to Overcome Real-World Military Training Limits

To test and train AI pilots, Shield AI acquired simulation leader Echelon. This is critical because physical training ranges are too small and limited to rehearse for vast, complex theaters like the Pacific. High-fidelity simulation becomes the only way to develop and validate autonomy at scale.

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng thumbnail

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng

TBPN·8 hours ago

Moda Founder Finds Users Expect API Access From Day One, Even for Consumer Products

The founder of AI design tool Moda discovered an immediate, high demand for an API. This signals a major shift in user behavior: even for consumer-facing creative tools, users now expect to chain products together into complex, automated workflows from launch, altering product roadmaps.

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng thumbnail

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng

TBPN·8 hours ago

Fundrise Uses Its 2 Million Investor Base as a Value-Add Sales Channel for Startups

Fundrise offers portfolio companies like Ramp direct marketing access to its massive investor base. This "network investing" model turns a fund's LPs into a powerful customer acquisition engine, providing a tangible value-add beyond capital that can significantly boost a startup's revenue.

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng thumbnail

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng

TBPN·8 hours ago

Fundrise's Public VC Fund Traded at a Massive Premium, Proving Huge Retail Demand for Private Tech

Experts predicted Fundrise's publicly traded venture fund (VCX) would trade at a discount to its net asset value (NAV). Instead, massive retail investor demand for access to top private tech companies like Anthropic caused it to trade at a significant premium, validating a new model for venture liquidity.

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng thumbnail

$2B Allergy Drug, ChatGPT Ads, Mansion Section | Billy Boman, Benjamin Miller, Faris Sbahi, Evan Loomis, Anvisha Pai, Ryan Tseng

TBPN·8 hours ago